GRI logo

GRI BIO INC

GRINASDAQ
🏆 #5511 by market capEarnings Nov 12US Equity
$2.15▲ $0.12 (+5.39%)
Live
🔔
Track GRI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.4%
7d▲ 4.4%
14d▲ 18.1%
30d▲ 7.8%
ytd▼ 68.4%
1y▼ 96.1%
🏦Market Cap
$193,139
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$2.14 – $2.17
52-Week Range
$1.36 – $64.12
Volume
$3.36B
Avg Volume
$2.64B
Shares Outstanding
89,832
Next Earnings
Nov 19, 2026

Fundamentals Snapshot

Annual Revenue
$91,971
Last Q Revenue
$25,644
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-5.35
Dividend Yield
0.00%
Dilution (1yr)
+1330.3%

Why Investors Own GRI

  • ✓High-growth profile — revenue up +38.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 26% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GRI logo

GRI BIO INC

GRI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +45.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▲ +18.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
94K▲ +1330.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▼ −$644K YoY
StockOtter · stockotter.space

About GRI BIO INC

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$2.73
▲ +27.0% Upside
High Target$3.13
Low Target$2.34
Based on 13 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

GRI BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift GRI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

GRI BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.